Clinical trial with bromperidol in psychotic states.
The author has given bromperidol to a first group of fifteen patients with a clear psychotic condition, mostly of the schizophrenic type. The results of this study show that this neuroleptic drug possesses potent antipsychotic properties, being thus very interesting in the treatment of productive psychosis. Its antimanic activity is, however, not pronounced. Therefore, it is not indicated in agitation states requiring heavy and immediate sedation. The general tolerability of the product is excellent. Its side-effects are mostly of the extrapyramidal type, generally mild and easily controlled by antiparkinson medications. Bromperidol, given in one single daily dose, is well accepted by the patients. It is therefore a valuable addition in the neuroleptic therapy as concerns prevention of relapses in psychotic conditions. Its stimulating properties on activity, concentration and socioprofessional adaptation make it particularly adequate for readaptation programs.
D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D006220:Haloperidol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D012559:Schizophrenia / Q000188:drug therapy*
D006220:Haloperidol